Switch studies in virologically suppressed patients

Switch ABC/3TC to TDF/FTC
SWIFT Study
Original article : Clin Infect Dis. 2013 Jun;56(11):1637-45 – R Campo
Last update : 28/03/2014

Dr Anton Pozniak
Chelsea and Westminster Hospital
London, UK

Design :


PI/r at baseline :

Objective :

  • Primary endpoint : proportion of patients with HIV-1 RNA < 200 c/mL through W48 (TLOVR failure = virologic failure [confirmed RNA ≥ 200 c/mL or last value ≥ 200 c/mL], premature discontinuation, ARV modification) ; lower limit of the 95% CI for the difference = - 12%

Baseline characteristics and patient disposition :

HIV RNA < 200 c/mL at W48, ITT-TLOVR

95% CI of the difference: - 5.1 ; 11.2

Virologic failure

Confirmed HIV RNA ≥ 200 c/mL or last value ≥ 200 c/mL


Adverse event leading to study drug discontinuation :

* Creatinine elevation
** Renal failure/dehydration
*** Multiple CNS symptoms and rash ; malaise and lower back pain ; sepsis ; rash ; decreased weight

eGFR (MDRD) (mL/min/1.73 m2) :

Fasting Lipids: median change from baseline to W48, mg/dL [mmol/L] :

  • No significant difference between groups in total cholesterol/HDL-c ratio at W48

* Wilcoxon rank-sum test

 

     

Back to Table of Contents

     
     
     
Copyright AEI 2010-2017 | Contact | Faculty and Disclosure | Terms of use | aei